BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Progenics Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-789-2800 Fax: 914-789-2817


View Clinical Trials from BioPharm Insight

Progenics Pharmaceuticals, Inc., of Tarrytown, NY is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development.

The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5 (in phase 1b studies). In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immuno-therapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA. A recombinant PSMA vaccine is in phase 1 clinical testing. The Company is also developing a cancer vaccine, GMK, in phase 3 clinical trials for the treatment of malignant melanoma.

Last Updated: 06-09-2006

 Key Statistics

Ownership: Public

Web Site: Progenics Pharmaceuticals, Inc.
Symbol: PGNX

 Company News
Progenics Pharmaceuticals, Inc. (PGNX) CEO, Mark R. Baker, To Present At 13th Annual Needham Healthcare Conference 4/8/2014 7:50:34 AM    More...
Progenics Pharmaceuticals, Inc. (PGNX) And Centre For Probe Development And Commercialization Announce Agreement To Manufacture Targeted Radiotherapeutic Candidate For Ultra-Orphan Indications 4/2/2014 9:16:14 AM    More...
Progenics Pharmaceuticals, Inc. (PGNX) Announces Fourth Quarter And Year-End 2013 Financial Results And Initiates Clinical Development Of Small Molecule Targeted Therapeutic 3/13/2014 8:54:31 AM    More...
Progenics Pharmaceuticals, Inc. (PGNX) Sets 4Q And Year-End 2013 Financial Results Call For March 13 3/11/2014 9:07:15 AM    More...
Progenics Pharmaceuticals, Inc. (PGNX) Sets 1Q 2014 Financial Results Call For March 13 3/5/2014 9:12:50 AM    More...
Progenics Pharmaceuticals, Inc. (PGNX) Announces Pricing Of Public Offering Of Common Stock 2/21/2014 7:15:42 AM    More...
Progenics Pharmaceuticals, Inc. (PGNX) CEO, Mark R. Baker, To Present At 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/7/2014 9:04:47 AM    More...
Progenics Pharmaceuticals, Inc. (PGNX) 1404 Imaging Agent Shows High Accuracy In Detecting Cancer Within The Prostate Gland In Interim Analysis Of Phase 2 Study 1/30/2014 4:42:45 PM    More...
Progenics Pharmaceuticals, Inc. (PGNX) Presents Positive Data From A Phase 2 Trial Of PSMA ADC In Patients With Chemotherapy Experienced Metastatic Castrate Resistant Prostate Cancer 1/30/2014 4:41:22 PM    More...
Progenics Pharmaceuticals, Inc. (PGNX) Announces The Appointment Of Karen Ferrante, M.D. To Its Board Of Directors 1/30/2014 8:55:55 AM    More...